Prevention of hepatitis C virus infection and spread in human liver chimeric mice by an anti‐CD81 monoclonal antibody

Changhua Ji, Yang Liu, Chandra Pamulapati, Sandhya Bohini, Georg Fertig, Michael Schraeml, Werner Rubas, Michael Brandt, Stefan Ries, Han Ma, Klaus Klumpp – 22 November 2014 – CD81 is a required receptor for hepatitis C virus (HCV) infection of human hepatocytes in vitro. We generated several high‐affinity anti‐human CD81 monoclonal antibodies (mAbs) that demonstrated potent, specific, and cross‐genotype inhibition of HCV entry.

Development of risk scoring system for stratifying population for hepatocellular carcinoma screening

Yi‐Chun Hung, Chih‐Lin Lin, Chun‐Jen Liu, Hung Hung, Shi‐Ming Lin, Shou‐Dong Lee, Pei‐Jer Chen, Shu‐Chun Chuang, Ming‐Whei Yu – 21 November 2014 – The age and risk level that warrants hepatocellular carcinoma (HCC) screening remains to be defined. To develop risk scores for stratifying average‐risk population for mass HCC screening, we conducted a pooled analysis using data from three cohorts involving 12,377 Taiwanese adults 20‐80 years of age. During 191,240.3 person‐years of follow‐up, 387 HCCs occurred.

Cre‐ativity in the liver: Transgenic approaches to targeting hepatic nonparenchymal cells

Stephen N. Greenhalgh, Kylie P. Conroy, Neil C. Henderson – 21 November 2014 – Rapid evolution in transgenic (Tg) mouse technology now permits cell‐specific and temporal control of fluorescent cell‐labeling and gene inactivation. Here, we discuss the principal strategies that have been utilized to target, label, and manipulate hepatic nonparenchymal cells, with emphasis on the utility of constitutive and inducible Cre‐lox systems.

Subscribe to